Shares of Poniard Pharmaceuticals Inc. (Nasdaq: PARD) rebounded by soaring 65 cents to close at $2.48 after reporting positive trial results for its chemotherapy drug picoplatin in colorectal cancer patients. Yesterday, the company said that picoplatin failed a trial for lung cancer patients.
Poniard Rebounds
November 17, 2009 at 16:20 PM EST
